Clinical Research in Cardiology

, Volume 105, Issue 12, pp 971–980 | Cite as

Similar hemodynamic decongestion with vasodilators and inotropes: systematic review, meta-analysis, and meta-regression of 35 studies on acute heart failure

  • Shiro Ishihara
  • Etienne Gayat
  • Naoki Sato
  • Mattia Arrigo
  • Said Laribi
  • Matthieu Legrand
  • Rui Placido
  • Philippe Manivet
  • Alain Cohen-Solal
  • William T. Abraham
  • Mariell Jessup
  • Alexandre Mebazaa
Original Paper

Abstract

Background

Acute heart failure (AHF) with reduced left-ventricular ejection fraction (LVEF) is often a biventricular congested state. The comparative effect of vasodilators and inotropes on the right- and/or left-sided congestion is unknown.

Methods and results

A systematic review, meta-analysis, and meta-regression of AHF studies using pulmonary artery catheter were performed using PubMed, Embase, and Cochrane library. Data from 35 studies, including 3016 patients, were studied. Included patients had a weighted mean age of 60 years, left-ventricular ejection fraction (LVEF) of 24 %, and plasma B-type natriuretic peptide (BNP) of 892 pg/ml. Both the left- and right-ventricular filling pressures were elevated: weighted mean pulmonary artery wedge pressure (PAWP) was 25 mmHg (range 17–31 mmHg) and right atrial pressure (RAP) 12 mmHg (range 7–18 mmHg). Vasodilators and inotropes had similar beneficial effects on PAWP [−6.3 mmHg (95 % CI −7.4 to −5.2 mmHg) and −5.8 mmHg (95 % CI −7.6 to −4.0 mmHg), respectively] and RAP [−2.9 mmHg (95 % CI −3.8 to −2.1 mmHg) and −2.8 mmHg (95 % CI −3.8 to −1.7 mmHg), respectively]. Among inotropes, inodilators, such as levosimendan, have greater beneficial effect on the left-ventricular filling pressure than dobutamine. Drug-induced improvement of PAWP tightly paralleled that of RAP with all studied drugs (r2 = 0.90, p < 0.001). Vasodilators and inotropes had no short-term effect of renal function.

Conclusion

The left- and right-sided filling pressures are similarly improved by vasodilators or inotropes, in AHF with reduced LVEF.

Keywords

Acute heart failure Inotropes Vasodilators Hemodynamics Congestion Decongestion Meta-analysis Meta-regression 

Notes

Acknowledgments

AM received speaker’s honoraria from The Medicines Company, Novartis, Orion, Roche, Servier, Vifor Pharma; AM received fee as member of advisory board and/or Steering Committee from Cardiorentis, The Medicine Company, Adrenomed, MyCartis and Critical Diagnostics. EG received fee as member of advisory board from Magnisense and Adrenomed.

Compliance with ethical standards

Conflict of interest

No conflicts of interest for the other coauthors.

Supplementary material

392_2016_1009_MOESM1_ESM.pdf (434 kb)
Supplementary material 1 Suppl Fig. 1–4: Comparison of changes in systemic hemodynamics between inotropes and vasodilators. Suppl Fig. 5: Comparison of safety parameters between inotropes and vasodilators. Suppl Fig. 6: Change in creatinine levels after drug administration. Only trials were studied, vasodilators are in blue, inotropes in red, and placebo arms in green (PDF 434 kb)
392_2016_1009_MOESM2_ESM.docx (47 kb)
Supplementary material 2 (DOCX 46 kb)

References

  1. 1.
    Dupont M, Mullens W, Tang WH (2011) Impact of systemic venous congestion in heart failure. Curr Heart Fail Rep 8(4):233–241CrossRefPubMedGoogle Scholar
  2. 2.
    Nikolaou M, Parissis J, Yilmaz MB, Seronde MF, Kivikko M, Laribi S, Paugam-Burtz C, Cai D, Pohjanjousi P, Laterre PF, Deye N, Poder P, Cohen-Solal A, Mebazaa A (2013) Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. Eur Heart J 34(10):742–749CrossRefPubMedGoogle Scholar
  3. 3.
    Follath F, Yilmaz MB, Delgado JF, Parissis JT, Porcher R, Gayat E, Burrows N, McLean A, Vilas-Boas F, Mebazaa A (2011) Clinical presentation, management and outcomes in the acute heart failure global survey of standard treatment (ALARM-HF). Intensive Care Med 37(4):619–626CrossRefPubMedGoogle Scholar
  4. 4.
    Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. J Stat Softw 36(3):1–48CrossRefGoogle Scholar
  5. 5.
    Albo C, Saal JP, Lellouche D, Habbal R, Benvenuti C, Deleuze P, Loisance D, Castaigne A, Dubois-Rande JL (1994) Additive haemodynamic effects of piroximone and prostacyclin in severe chronic heart failure. Eur Heart J 15(4):528–533PubMedGoogle Scholar
  6. 6.
    Binanay C, Califf RM, Hasselblad V, O’Connor CM, Shah MR, Sopko G, Stevenson LW, Francis GS, Leier CV, Miller LW, Investigators E, Coordinators ES (2005) Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 294(13):1625–1633CrossRefPubMedGoogle Scholar
  7. 7.
    Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz MM, Liang CS, Neibaur M, Haught WH, LeJemtel TH (2000) Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 343(4):246–253CrossRefPubMedGoogle Scholar
  8. 8.
    Cotter G, Kaluski E, Stangl K, Pacher R, Richter C, Milo-Cotter O, Perchenet L, Kobrin I, Kaplan S, Rainisio M, Frey A, Neuhart E, Vered Z, Dingemanse J, Torre-Amione G (2004) The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure. Eur J Heart Fail 6(5):601–609CrossRefPubMedGoogle Scholar
  9. 9.
    Dupont M, Mullens W, Skouri HN, Abrahams Z, Wu Y, Taylor DO, Starling RC, Tang WH (2012) Prognostic role of pulmonary arterial capacitance in advanced heart failure. Circ Heart Fail. 5(6):778–785CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Erdmann E, Semigran MJ, Nieminen MS, Gheorghiade M, Agrawal R, Mitrovic V, Mebazaa A (2013) Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur Heart J 34(1):57–67CrossRefPubMedGoogle Scholar
  11. 11.
    Erlemeier HH, Kupper W, Bleifeld W (1992) Effect of dobutamine on pulmonary gas exchange in patients with severe heart failure. Eur Heart J 13(11):1545–1548PubMedGoogle Scholar
  12. 12.
    Fifer MA, Colucci WS, Lorell BH, Jaski BE, Barry WH (1985) Inotropic, vascular and neuroendocrine effects of nifedipine in heart failure: comparison with nitroprusside. J Am Coll Cardiol 5(3):731–737CrossRefPubMedGoogle Scholar
  13. 13.
    Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L, Steering C (2002) Investigators of the Levosimendan Infusion versus Dobutamine S. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360(9328):196–202CrossRefPubMedGoogle Scholar
  14. 14.
    Friesecke S, Heinrich A, Abel P, Felix SB (2009) Comparison of pulmonary artery and aortic transpulmonary thermodilution for monitoring of cardiac output in patients with severe heart failure: validation of a novel method. Crit Care Med 37(1):119–123CrossRefPubMedGoogle Scholar
  15. 15.
    Gheorghiade M, Blair JE, Filippatos GS, Macarie C, Ruzyllo W, Korewicki J, Bubenek-Turconi SI, Ceracchi M, Bianchetti M, Carminati P, Kremastinos D, Valentini G, Sabbah HN, Investigators H-H (2008) Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol 51(23):2276–2285CrossRefPubMedGoogle Scholar
  16. 16.
    Gheorghiade M, Greene SJ, Filippatos G, Erdmann E, Ferrari R, Levy PD, Maggioni A, Nowack C, Mebazaa A, Investigators C (2012) Coordinators. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J Heart Fail 14(9):1056–1066CrossRefPubMedGoogle Scholar
  17. 17.
    Grose R, Strain J, Greenberg M, LeJemtel TH (1986) Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure. J Am Coll Cardiol 7(5):1107–1113CrossRefPubMedGoogle Scholar
  18. 18.
    Guglin M, Rivero A, Matar F, Garcia M (2011) Renal dysfunction in heart failure is due to congestion but not low output. Clin Cardiol 34(2):113–116CrossRefPubMedGoogle Scholar
  19. 19.
    Knebel F, Schimke I, Diaz Ramirez I, Schattke S, Eddicks S, Borges AC, Baumann G (2009) Hemodynamic improvement of acutely decompensated heart failure patients is associated with decreasing levels of NT-proBNP. Int J Cardiol 134(2):260–263CrossRefPubMedGoogle Scholar
  20. 20.
    Knebel F, Schimke I, Pliet K, Schattke S, Martin S, Borges AC, Baumann G (2005) NT-ProBNP in acute heart failure: correlation with invasively measured hemodynamic parameters during recompensation. J Card Fail 11(5 Suppl):S38–S41CrossRefPubMedGoogle Scholar
  21. 21.
    Kobayashi S, Susa T, Tanaka T, Murakami W, Fukuta S, Okuda S, Doi M, Wada Y, Nao T, Yamada J, Okamura T, Yano M, Matsuzaki M (2012) Low-dose beta-blocker in combination with milrinone safely improves cardiac function and eliminates pulsus alternans in patients with acute decompensated heart failure. Circ J 76(7):1646–1653CrossRefPubMedGoogle Scholar
  22. 22.
    Masuyama T, Lee JM, Nagano R, Nariyama K, Yamamoto K, Naito J, Mano T, Kondo H, Hori M, Kamada T (1995) Doppler echocardiographic pulmonary venous flow-velocity pattern for assessment of the hemodynamic profile in acute congestive heart failure. Am Heart J 129(1):107–113CrossRefPubMedGoogle Scholar
  23. 23.
    Mills RM, LeJemtel TH, Horton DP, Liang C, Lang R, Silver MA, Lui C, Chatterjee K (1999) Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol 34(1):155–162CrossRefPubMedGoogle Scholar
  24. 24.
    Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Miric M, Moiseyev VS, Kobalava Z, Nitsche K, Forssmann WG, Luss H, Meyer M (2006) Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 27(23):2823–2832CrossRefPubMedGoogle Scholar
  25. 25.
    Mizutani T, Inomata T, Watanabe I, Maekawa E, Yanagisawa T, Shinagawa H, Koitabashi T, Takeuchi I, Izumi T (2011) Comparison of nitrite compounds and carperitide for initial treatment of acute decompensated heart failure. Int Heart J. 52(2):114–118CrossRefPubMedGoogle Scholar
  26. 26.
    Monrad ES, Baim DS, Smith HS, Lanoue AS (1986) Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. Circulation 73(3 Pt 2):168–174 (III) Google Scholar
  27. 27.
    Mullens W, Abrahams Z, Francis GS, Skouri HN, Starling RC, Young JB, Taylor DO, Tang WH (2008) Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol 52(3):200–207CrossRefPubMedGoogle Scholar
  28. 28.
    Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WH (2009) Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 53(7):589–596CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    O’Neill JO, Bott-Silverman CE, McRae AT 3rd, Troughton RW, Ng K, Starling RC, Young JB (2005) B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure. Am Heart J 149(2):363–369CrossRefPubMedGoogle Scholar
  30. 30.
    Ponikowski P, Mitrovic V, Ruda M, Fernandez A, Voors AA, Vishnevsky A, Cotter G, Milo O, Laessing U, Zhang Y, Dahlke M, Zymlinski R, Metra M (2014) A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Eur Heart J 35(7):431–441. doi:10.1007/s00392-016-1009-6 CrossRefPubMedGoogle Scholar
  31. 31.
    Committee for the VI. Publication (2002) Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287(12):1531–1540Google Scholar
  32. 32.
    Renard M, Jacobs P, Dechamps P, Dresse A, Bernard R (1983) Hemodynamic and clinical response to three-day infusion of sulmazol (AR-L 115 BS) in severe congestive heart failure. Chest 84(4):408–413CrossRefPubMedGoogle Scholar
  33. 33.
    Ritter S, Rudiger A, Maggiorini M (2009) Transpulmonary thermodilution-derived cardiac function index identifies cardiac dysfunction in acute heart failure and septic patients: an observational study. Crit Care 13(4):R133CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Saal JP, Habbal R, Estagnasie P, Lellouche D, Castaigne A, Dubois-Rande JL (1994) Effects of piroximone on the right ventricular function in severe heart failure patients. Intensive Care Med 20(5):341–347CrossRefPubMedGoogle Scholar
  35. 35.
    Seino Y, Momomura S, Takano T, Hayakawa H, Katoh K (1996) Multicenter, double-blind study of intravenous milrinone for patients with acute heart failure in Japan. Japan Intravenous Milrinone Investigators. Crit Care Med 24(9):1490–1497CrossRefPubMedGoogle Scholar
  36. 36.
    Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, Hutchins S, Leier CV, LeJemtel TH, Loh E, Nicklas J, Ogilby D, Singh BN, Smith W (2000) Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 102(18):2222–2227CrossRefPubMedGoogle Scholar
  37. 37.
    Tanaka K, Kato K, Takano T, Katagiri T, Asanoi H, Nejima J, Nakashima M, Kamijo T, Sakanashi M (2010) Acute effects of intravenous nicorandil on hemodynamics in patients hospitalized with acute decompensated heart failure. J Cardiol 56(3):291–299CrossRefPubMedGoogle Scholar
  38. 38.
    Torre-Amione G, Young JB, Colucci WS, Lewis BS, Pratt C, Cotter G, Stangl K, Elkayam U, Teerlink JR, Frey A, Rainisio M, Kobrin I (2003) Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 42(1):140–147CrossRefPubMedGoogle Scholar
  39. 39.
    Zilinski JL, Shah RV, Gaggin HK, Gantzer ML, Wang TJ, Januzzi JL (2012) Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy. Crit Care 16(4):R135CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Mebazaa A, Karpati P, Renaud E, Algotsson L (2004) Acute right ventricular failure–from pathophysiology to new treatments. Intensive Care Med 30(2):185–196CrossRefPubMedGoogle Scholar
  41. 41.
    Grodin JL, Drazner MH, Dupont M, Mullens W, Taylor DO, Starling RC, Tang WH (2015) A disproportionate elevation in right ventricular filling pressure, in relation to left ventricular filling pressure, is associated with renal impairment and increased mortality in advanced decompensated heart failure. Am Heart J 169(6):806–812CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Drazner MH, Velez-Martinez M, Ayers CR, Reimold SC, Thibodeau JT, Mishkin JD, Mammen PP, Markham DW, Patel CB (2013) Relationship of right- to left-sided ventricular filling pressures in advanced heart failure: insights from the ESCAPE trial. Circ Heart Fail 6(2):264–270CrossRefPubMedGoogle Scholar
  43. 43.
    Mebazaa A, Yilmaz MB, Levy P, Ponikowski P, Peacock WF, Laribi S, Ristic AD, Lambrinou E, Masip J, Riley JP, McDonagh T, Mueller C, deFilippi C, Harjola VP, Thiele H, Piepoli MF, Metra M, Maggioni A, McMurray J, Dickstein K, Damman K, Seferovic PM, Ruschitzka F, Leite-Moreira AF, Bellou A, Anker SD, Filippatos G (2015) Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail 17(6):544–558CrossRefPubMedGoogle Scholar
  44. 44.
    McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A (2012) Guidelines ESCCfP. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33(14):1787–1847CrossRefPubMedGoogle Scholar
  45. 45.
    Nohria A, Hasselblad V, Stebbins A, Pauly DF, Fonarow GC, Shah M, Yancy CW, Califf RM, Stevenson LW, Hill JA (2008) Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol 51(13):1268–1274CrossRefPubMedGoogle Scholar
  46. 46.
    Shah SJ, Blair JE, Filippatos GS, Macarie C, Ruzyllo W, Korewicki J, Bubenek-Turconi SI, Ceracchi M, Bianchetti M, Carminati P, Kremastinos D, Grzybowski J, Valentini G, Sabbah HN, Gheorghiade M, HORIZON-HF Investigators (2009) Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial. Am Heart J 157(6):1035–1041CrossRefPubMedGoogle Scholar
  47. 47.
    VMAC Investigators (2002) Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287(12):1531–1540Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Shiro Ishihara
    • 1
    • 2
  • Etienne Gayat
    • 2
    • 3
    • 4
  • Naoki Sato
    • 1
  • Mattia Arrigo
    • 2
    • 4
    • 5
  • Said Laribi
    • 2
    • 3
    • 6
  • Matthieu Legrand
    • 2
    • 3
    • 4
  • Rui Placido
    • 2
    • 7
  • Philippe Manivet
    • 2
    • 8
    • 9
  • Alain Cohen-Solal
    • 2
    • 3
    • 10
  • William T. Abraham
    • 11
  • Mariell Jessup
    • 12
  • Alexandre Mebazaa
    • 2
    • 3
    • 4
  1. 1.Cardiology DepartmentSteel Memorial Yawata HospitalKitakyushuJapan
  2. 2.Inserm UMR-S 942ParisFrance
  3. 3.University Paris Diderot, Sorbonne Paris CitéParisFrance
  4. 4.Department of Anesthesia and Critical MedicineHôpitaux Universitaires Saint Louis-Lariboisière, AP-HPParisFrance
  5. 5.Division of Cardiology, University Heart CenterUniversity Hospital ZurichZurichSwitzerland
  6. 6.Department of Emergency MedicineHôpitaux Universitaires Saint Louis-Lariboisière, AP-HPParisFrance
  7. 7.Hospital Santa Maria, Serv Cardiologia ILisbon Academic Medical Centre, CCULLisbonPortugal
  8. 8.Department of BiochemistryLariboisière HospitalParis Cedex 10France
  9. 9.France Center for Biological ResourcesLariboisière HospitalParisFrance
  10. 10.Department of CardiologyHôpitaux Universitaires Saint Louis-LariboisièreParisFrance
  11. 11.Division of Cardiovascular MedicineThe Ohio State UniversityColumbusUSA
  12. 12.The Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations